4/24
07:05 am
rgnx
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Low
Report
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
4/17
07:29 am
rgnx
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures [Yahoo! Finance]
Low
Report
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures [Yahoo! Finance]
4/12
12:11 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock.
4/11
02:04 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/3
02:04 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/28
01:30 pm
rgnx
REGENXBIO Sees Positive Results For Macular Degeneration Therapy [Yahoo! Finance]
Low
Report
REGENXBIO Sees Positive Results For Macular Degeneration Therapy [Yahoo! Finance]
3/28
07:21 am
rgnx
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD [Yahoo! Finance]
Medium
Report
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD [Yahoo! Finance]
3/28
07:05 am
rgnx
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
Medium
Report
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
3/27
04:05 pm
rgnx
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
Medium
Report
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
3/21
02:06 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/13
08:12 am
rgnx
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? [Yahoo! Finance]
Low
Report
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? [Yahoo! Finance]
3/11
11:00 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/11
11:00 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/11
12:27 pm
rgnx
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform [Seeking Alpha]
Low
Report
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform [Seeking Alpha]
3/11
10:13 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
3/11
07:35 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/11
07:05 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences
Low
Report
REGENXBIO to Participate in Upcoming Investor Conferences
3/8
09:28 am
rgnx
Regenxbio raised to Buy at RBC on pivot to Duchenne [Seeking Alpha]
Medium
Report
Regenxbio raised to Buy at RBC on pivot to Duchenne [Seeking Alpha]
3/8
08:21 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $35.00 price target on the stock, up previously from $20.00.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $35.00 price target on the stock, up previously from $20.00.
3/8
01:42 am
rgnx
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares [Yahoo! Finance]
Low
Report
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares [Yahoo! Finance]
3/7
02:25 pm
rgnx
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates [Yahoo! Finance]
Low
Report
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates [Yahoo! Finance]
3/7
10:24 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
3/7
08:00 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at Barclays PLC from $45.00 to $55.00. They now have an "overweight" rating on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at Barclays PLC from $45.00 to $55.00. They now have an "overweight" rating on the stock.
3/7
06:31 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
3/6
11:20 pm
rgnx
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
Low
Report
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants